Company news

Zentalis Pharmaceuticals, Inc. news in 2021

Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021

December 1, 2021

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

November 16, 2021

Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

November 9, 2021

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

September 12, 2021

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

August 31, 2021

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

August 11, 2021

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

August 1, 2021

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

August 1, 2021

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 30, 2021

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated

June 27, 2021

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

June 27, 2021

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

June 27, 2021

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

May 16, 2021

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

April 11, 2021

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

April 9, 2021

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

March 24, 2021

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021

March 9, 2021

Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors

February 9, 2021

Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials

January 5, 2021

Decks in 2021